

Neurotech Signs New Development Agreement for Cannabinoid Therapies

Key Points:

- Neurotech enters partnership agreement with RH Farma Dooel Skopje (RH Pharma), a subsidiary of European Cannabis Company (ECC), a European leader in the development and scale-up of cannabis-based products for pharmaceutical applications
- The development aims to generate a strain-agnostic, pharmaceutical-grade broad spectrum cannabinoid drug product suitable for paediatric patients with neurodevelopmental disorders based on RH Pharma's proprietary CO₂ extraction technology
- Aligns with Neurotech's proprietary composition and formulation consisting of certain cannabinoids at specific concentrations that has demonstrated significant improvement in patients with progressive neuroinflammatory disorders including autism, Rett Syndrome and PANDAS/PANS
- An Initial upfront payment of €25,000 with additional services as requested by Neurotech with an initial term of 12 months

Neurotech International Limited (ASX: NTI) ('Neurotech', 'NTI' or 'the Company') a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today announces the signing of a binding Development Agreement with RH Pharma, a European leader in the development and scale-up of cannabis-based products for pharmaceutical applications.

Under the agreement, Neurotech will harness ECC's advanced capabilities in product development, manufacturing, and scale up to meet the increasing global demand for high-quality cannabis-derived pharmaceuticals. Under the development plans, RH Pharma will undertake a controlled recombination process of highly purified cannabinoids from standard cannabis strains under Good Manufacturing Practice (GMP), and relevant other pharmaceutical standards, into a broad-spectrum cannabinoid drug product reflecting Neurotech's compositional standards, and that meets global regulatory standards. The partnership allows both companies to leverage their expertise to deliver consistent, high-performing products to international markets.

The Development Agreement will enable Neurotech to expand into new markets while ensuring production at the highest pharmaceutical standards. Neurotech's commitment to innovation has culminated in the development of proprietary technologies and processes that enhance product efficacy and safety.

Dr Anthony Filippis, CEO and Managing Director of Neurotech International said "As we accelerate our plans for registration of NTI64 in Australia via a provisional registration strategy initially, it will be important for Neurotech to scale production to meet future product demand upon regulatory approval(s). Our commitment to regulatory compliance and quality is further strengthened by collaborations with leading medical institutions and key clinicians, reinforcing our position within the industry. We are delighted to partner with ECC, a company renowned for its expertise in cannabis product development. This agreement not only accelerates our global growth strategy but also ensures we can deliver premium-quality products with unparalleled consistency and scalability, independent of strain-specific limitations.

"ECC is thrilled to collaborate with Neurotech on this transformative partnership," said **Rebeka Levy, General Manager** of European Cannabis Company. "Our shared vision for innovation and international expansion positions us to deliver exceptional products to meet growing global demand."

The Development Agreement aligns with the Company's focus on innovation and making a meaningful difference in the lives of those affected by neurological disorders.

Authority

This announcement has been authorised for release by the Board of Neurotech International Limited.

For further information contact us via: info@neurotechinternational.com

About Neurotech

Neurotech International Limited (ASX:NTI) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.

About RH Farma Dooel Skopje (RH Pharma)

RH Pharma is a pharmaceutical company based in Skopje, North Macedonia, specializing in the cultivation and production of medical cannabis products. Their operations are conducted in compliance with EU Good Manufacturing Practice (GMP) standards, ensuring high-quality production processes. In March 2024, RH Pharma received a renewal of their EU German GMP certification for both cultivation and extraction facilities, valid for another three years. Their facilities are capable of producing up to 8 tonnes of GMP-grade medical cannabis flower and over 250,000 bottles of GMP-grade extract annually.

About European Cannabis Company (ECC)

European Cannabis Company is one of Europe's most advanced and established providers of cannabis-based pharmaceutical products. With a strong focus on quality, compliance, and innovation, ECC is a trusted partner for brands seeking to expand into international markets.